CNTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

-0.094

-57.14%

-0.110

+120%

Estimates Revision

The market is revising No Change the revenue expectations for Context Therapeutics Inc. (CNTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 15.71%.

EPS Estimates for FY2025

Revise Upward

+3.93%

In Past 3 Month

Stock Price

Go Up

+15.71%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.75 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

4.75

High

5.00

Current: 0.000

Low

4.00

Averages

4.75

High

5.00

H.C. Wainwright

Buy

maintain

$4 -> $5

2025-11-06

Reason

H.C. Wainwright

Price Target

$4 -> $5

2025-11-06

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Context Therapeutics to $5 from $4 and keeps a Buy rating on the shares following the Q3 report. The company noted a confirmed partial response in Cohort 3 for a patient with platinum resistant ovarian cancer, which is a "highly positive sign of activity," the analyst tells investors in a research note.

Guggenheim

Buy

initiated

2025-09-17

Reason

Guggenheim

Price Target

2025-09-17

initiated

Buy

Reason

Guggenheim initiated coverage of Context Therapeutics with a Buy rating and $5 price target.

Guggenheim

Buy

initiated

2025-09-17

Reason

Guggenheim

Price Target

2025-09-17

initiated

Buy

Reason

Guggenheim initiated coverage of Context Therapeutics with a Buy rating and $5 price target. The firm's investment thesis on the stock is centered on the company's differentiated approach to addressing \"clinically validated but challenging\" targets on solid tumors, which collectively represent a significant $30B U.S. total addressable market in aggregate across focus tumor type, the analyst tells investors in a research note. With shares trading at zero enterprise value, there is \"asymmetric risk/reward\" for Context Therapeutics, Guggenheim added.

H.C. Wainwright

Buy -> Buy

downgrade

$5 -> $4

2025-08-07

Reason

H.C. Wainwright

Price Target

$5 -> $4

2025-08-07

downgrade

Buy -> Buy

Reason

H.C. Wainwright lowered the firm's price target on Context Therapeutics to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.

Piper Sandler

Overweight

downgrade

2025-06-26

Reason

Piper Sandler

Price Target

2025-06-26

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Context Therapeutics to $4 from $4.50 and keeps an Overweight rating on the shares after assuming coverage. Context Therapeutics is focused on the emerging T-cell engager modality, which has been validated by several recent clinical milestones and strategic acquisitions, the analyst tells investors in a research note.

William Blair

Matt Phipps

Buy

Initiates

n/a

2025-04-21

Reason

William Blair

Matt Phipps

Price Target

n/a

2025-04-21

Initiates

Buy

Reason

William Blair initiated coverage of Context Therapeutics with an Outperform rating. The biopharmaceutical industry is entering a phase of significant advancements in the development of T-cell engagers for solid tumors and Context stands to benefit from the knowledge gained by the field in developing its three wholly owned programs, the analyst tells investors in a research note. The firm believes Claudin 6 is an ideal target for CD3-based TCEs, given the limited expression on healthy tissues. Blair thinks the readout of initial results in 2026 will be a "significant inflection point for Context shares given the significant potential of this asset alone."

Valuation Metrics

The current forward P/E ratio for Context Therapeutics Inc (CNTX.O) is -3.53, compared to its 5-year average forward P/E of -2.74. For a more detailed relative valuation and DCF analysis to assess Context Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.74

Current PE

-3.53

Overvalued PE

-0.47

Undervalued PE

-5.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.26

Undervalued EV/EBITDA

-1.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

-0.54

Current PS

0.00

Overvalued PS

2.83

Undervalued PS

-3.92

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNTX News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

5.0

01-05Benzinga

GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement

6.0

2025-12-22Benzinga

BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target

People Also Watch

Frequently Asked Questions

What is Context Therapeutics Inc (CNTX) stock price today?

The current price of CNTX is 1.62 USD — it has increased 1.25 % in the last trading day.

What is Context Therapeutics Inc (CNTX)'s business?

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.

What is the price predicton of CNTX Stock?

What is Context Therapeutics Inc (CNTX)'s revenue for the last quarter?

Context Therapeutics Inc revenue for the last quarter amounts to -10.61M USD, decreased -43.26 % YoY.

What is Context Therapeutics Inc (CNTX)'s earnings per share (EPS) for the last quarter?

Context Therapeutics Inc. EPS for the last quarter amounts to -6578864.00 USD, increased 239.00 % YoY.

What changes have occurred in the market's expectations for Context Therapeutics Inc (CNTX)'s fundamentals?

How many employees does Context Therapeutics Inc (CNTX). have?

Context Therapeutics Inc (CNTX) has 12 emplpoyees as of January 09 2026.

What is Context Therapeutics Inc (CNTX) market cap?

Today CNTX has the market capitalization of 147.01M USD.